The new contraindication follows the early termination of the ARTEMIS-IPF study, which was investigating the potential of ambrisentan to slow disease progression in patients with IPF. Evaluation of the primary endpoint components indicated higher rates of respiratory hospitalisation, mortality and decreases in respiratory function in patients who received ambrisentan than in those on placebo.
The most up-to-date drug information at your fingertips.
- Get the prescribing support you need.
- Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Potential sensitising agents in eye drops and ointments.
Join us for the MIMS Workshops Respiratory and Allergy...
Hormone doses and costs of HRT preparations.
Widespread false diagnosis of COPD is exposing patients to unnecessary medication risks, study suggests
Patients are being unnecessarily exposed to the adverse...